2509447-07-6
2509447-07-6
Chemical Structure
Amubarvimab
Synonym(s): BRII-196
- CAS No.: 2509447-07-6
- Formula:N/A
- Molecular Weight:(143.84 kDa)
IUPAC Name: (4-hydroxyphenyl)(tetrahydro-2H-pyran-2-yl)methanone
SMILES: [Amubarvimab]
Biological Activity:
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amubarvimab | 95.00% | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [Content Brief]
- [2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. [Content Brief]
